GEN Exclusives

More »

GEN News Highlights

More »
Jan 15, 2008

Genzyme to Pursue Prognostic Test for NSCLC with License from Moffitt

  • Genzyme obtained exclusive, worldwide diagnostic testing rights from Moffitt Cancer Center to its discovery of two proteins linked to non-small-cell lung cancer (NSCLC) treatment response. Genzyme plans on developing a test that can be used to guide first-line treatment of platinum drugs and gemcitabine.

    Gerold Bepler, M.D., reportedly showed that the expression levels of two proteins, RRM1 and ERCC1, correlate with patient response to platinum drugs and gemcitabine. Through this license, Genzyme plans to develop and market a test that can be used to measure the expression levels of these proteins in NSCLC patients.

    Genzyme will make milestone payments to Moffitt. The company will also provide running royalties on the sales of licensed services and products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?